Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)

NCT06625775 is registered in ClinicalTrials.gov with TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) as lead sponsor.

NCT NCT06625775
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06625775 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-10203 in Subjects With Advanced Solid Tumors (The BREAKER-101 Study)
Lead sponsor
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
Phase
Phase 1
Overall status
Recruiting
Start date
October 29, 2024
Completion date
November 30, 2028
Enrollment
392 (estimated)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

advanced breast cancer, advanced lung cancer, her2 mutation-related tumors, her2-positive advanced breast cancer, her2-positive metastatic breast cancer, hr-positive, her2-negative advanced breast cancer, kras mutant metastatic colorectal cancer, metastatic breast cancer, metastatic colorectal cancer, metastatic lung cancer, solid tumor, adult